KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Shares Outstanding (Diluted Average): 2009-2024

Historic Shares Outstanding (Diluted Average) for Teva Pharmaceutical Industries (TEVA) over the last 12 years, with Dec 2024 value amounting to $1.1 billion.

  • Teva Pharmaceutical Industries' Shares Outstanding (Diluted Average) rose 2.74% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 2.74%. This contributed to the annual value of $1.1 billion for FY2024, which is 1.07% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Shares Outstanding (Diluted Average) stood at $1.1 billion for FY2024, which was up 1.07% from $1.1 billion recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Shares Outstanding (Diluted Average) peaked at $1.1 billion during FY2024, and registered a low of $1.1 billion during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $1.1 billion (2023), whereas its average is $1.1 billion.
  • Data for Teva Pharmaceutical Industries' Shares Outstanding (Diluted Average) shows a peak YoY increased of 1.10% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Shares Outstanding (Diluted Average) stood at $1.1 billion in 2020, then climbed by 1.10% to $1.1 billion in 2021, then climbed by 0.27% to $1.1 billion in 2022, then grew by 0.81% to $1.1 billion in 2023, then rose by 1.07% to $1.1 billion in 2024.